MEDNAX (NYS: MD) reported earnings on July 31. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), MEDNAX beat expectations on revenues and earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share grew.
Margins dropped across the board.
MEDNAX booked revenue of $449.5 million. The 14 analysts polled by S&P Capital IQ looked for a top line of $437.1 million on the same basis. GAAP reported sales were 14% higher than the prior-year quarter's $393.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.22. The 15 earnings estimates compiled by S&P Capital IQ anticipated $1.19 per share. GAAP EPS of $1.22 for Q2 were 6.1% higher than the prior-year quarter's $1.15 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 34.6%, 150 basis points worse than the prior-year quarter. Operating margin was 22.2%, 150 basis points worse than the prior-year quarter. Net margin was 13.5%, 70 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $457.6 million. On the bottom line, the average EPS estimate is $1.26.
Next year's average estimate for revenue is $1.78 billion. The average EPS estimate is $4.71.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 181 members out of 186 rating the stock outperform, and five members rating it underperform. Among 55 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 53 give MEDNAX a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MEDNAX is outperform, with an average price target of $76.54.
If you're interested in health care stocks like MEDNAX, you might want to expand your horizons to find maximum returns. Follow the money and meet a prime candidate for major returns in our new report, "Discover the Next Rule-Breaking Multibagger." Get instant access to this free report.
- Add MEDNAX to My Watchlist.
The article MEDNAX Beats on Both Top and Bottom Lines originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is the co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.